16/09/2026
EPSM 2026 SPEAKER SPOTLIGHT
Plenary Session: Radioiodine to Radioligands: Dosimetry, Quantitative PET and the Future of Precision Oncology, Prof Michael Hoffman.
Join us in Brisbane from 22-25 November 2026 for an or the plenary session, "Radioiodine to Radioligands: Dosimetry, Quantitative PET and the Future of Precision Oncology."
An internationally recognised leader in nuclear medicine and theranostics, Professor Michael Hofman has helped shape the global adoption of PSMA PET imaging and radioligand therapy in prostate cancer.
Recognised as a Clarivate Highly Cited Researcher, he is among the world's most influential researchers, with his landmark clinical trials transforming cancer diagnosis and treatment worldwide.
Don't miss this opportunity to hear Prof Hofman's insights on the future of precision oncology at EPSM 2026!
Register here: https://epsm.org.au/registration